The Cancer Bioengineering Collaborative announced the projects that were selected for its first round of seed grants. Photo via Rice.edu

Five cancer-fighting research projects were named inaugural recipients of a new grant program founded by two Houston institutions.

Last summer, Rice University and The University of Texas MD Anderson Cancer Center announced they were teaming up to form the new Cancer Bioengineering Collaborative. The shared initiative, created to form innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment, recently launched with an event at the TMC3 Collaborative Building in Helix Park.

At the gathering, the Cancer Bioengineering Collaborative announced the projects that were selected for its first round of seed grants.

  • “Enhancing CAR-T immunotherapy via precision CRISPR/Cas-based epigenome engineering of high value therapeutic gene targets,” led by Isaac Hilton, associate professor of biosciences and bioengineering at Rice and a Cancer Research and Prevention Institute of Texas (CPRIT) scholar; and Michael Green, associate professor of lymphoma/myeloma at MD Anderson.
  • “Nanocluster and KRAS inhibitor-based combination therapy for pancreatic ductal adenocarcinoma,” led by Linlin Zhang, assistant research professor of bioengineering at Rice; and Haoqiang Ying, associate professor of molecular and cellular oncology at MD Anderson.
  • “Engineering tumor-infiltrating fusobacteriumas a microbial cancer therapy,” led by Jeffrey Tabor, professor of bioengineering at Rice; and Christopher Johnston, associate professor of genomic medicine and director of microbial genomics within the Platform for Innovative Microbiome and Translational Research at MD Anderson.
  • “Preclinical study of nanoscale TRAIL liposomes as a neoadjuvant therapy for colorectal cancer liver metastasis,” led by Michael King, the E.D. Butcher Professor of Bioengineering at Rice, CPRIT scholar and special adviser to the provost on life science collaborations with the Texas Medical Center; and Xiling Shen, professor of gastrointestinal medical oncology at MD Anderson.
  • “Deciphering molecular mechanisms of cellular plasticity in MDS progression,” led by Ankit Patel, assistant professor of electrical and computer engineering at Rice and of neuroscience at Baylor College of Medicine; and Pavan Bachireddy, assistant professor of hematopoietic biology and malignancy and lymphoma/myeloma at MD Anderson.

The event was a who’s who of Houston-based cancer specialists. Speakers included our city’s favorite Nobel laureate, Jim Allison, director of the James P. Allison Institute, as well as MD Anderson’s vice president of research, Eyal Gottlieb. Attendees were welcomed by the leaders of the initiative, Rice’s Gang Bao and MD Anderson’s Jeffrey Molldrem.

“This collaborative initiative builds on the strong foundation of our existing relationship, combining Rice’s expertise in bioengineering, artificial intelligence and nanotechnology with MD Anderson’s unmatched insights in cancer care and research,” Rice’s president Reginald DesRoches says at the event. “This is a momentous occasion to advance cancer research and treatment with the innovative fusion of engineering and medicine.”

The collaboration is part of Rice’s 10-year strategic plan for leadership in health innovation, called “Momentous: Personalized Scale for Global Impact.” Its goals include a commitment to responsible use of cutting-edge AI.

“As both institutions continue to make breakthroughs every day, we hope this collaborative will enable us to tackle the complex challenges of cancer care and treatment more effectively, ultimately improving the lives of patients here in Houston and beyond," Carin Hagberg, senior vice president and chief academic officer at MD Anderson, adds. "Whether our researchers are working on the South Campus or within the hedges of Rice, this collaborative will strengthen each other’s efforts and push the boundaries of what is possible in cancer.”

MD Anderson's lab led by Nobel laureate James Allison has secured a $5 million donation. Photo courtesy of MD Anderson Cancer Center

Cancer-fighting Houston lab led by Nobel laureate receives $5M grant at annual event

supporting research

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center scored a $5 million gift at its second annual symposium.

On behalf of Mayor John Whitmire, Oct. 10, 2024 was named “James P. Allison Institute Day,” and it was also the day that the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park greeted 900 attendees for the scientific symposium, entitled “Immunotherapy in Space and Time: The Tumor Microenvironment.”

Allison, who won the Nobel Prize in 2018, leads his namesake institute that was founded in 2022 to advance translational and clinical within cancer to create new, synergetic therapies. In addition to his role as director of the institute, he is regental professor and chair of Immunology at MD Anderson.

At the symposium, Jack and Judi Johnson presented a $5 million gift to the Allison Institute on behalf of the David and Eula Wintermann Foundation, a private organization dedicated to funding the advancement of medical education and research. A longtime supporter of MD Anderson, the foundation’s donation will go towards recruitment and technology for the institute, as well help fund clinical trials.

The money will help support several researchers, who will be known as Wintermann Scholars. The chosen great minds run the gamut from early career scientists to world-renowned experts in fields including immunotherapy, genetics, cancer biology, data science, bioinformatics, spatial profiling or the microbiome.

It was clear to us that the work happening within the Allison Institute has the potential to transform the lives of so many patients,” said Johnson, president of the Wintermann Foundation. “Our hope is that, with our support, we can help close the distance from the lab to the clinic so the incredible advancements underway can sooner help more cancer patients and their families.”

But the attendees on Oct. 10 learned far more than that. They were treated to a conversation between Allison and Carolyn Bertozzi, also a Nobel laureate, moderated by Alice Park, a senior health correspondent at Time. Park also took part in a fireside chat with Allison institute leaders, joined by MD Anderson President Peter WT Pisters and Chief Scientific Officer Giulio Draetta. Additional sessions also included presentations from big names like Mark Dawson, Elizabeth Jaffee, and Philip Greenberg.

“Spatial biology is a rapidly expanding field that offers tremendous new insights into immunobiology that were not possible just a few short years ago. Understanding how immune cells interact with their neighbors and with tumor cells in space and time will enable us to bring forward new strategies to improve immunotherapy outcomes,” said Allison. “We are proud to host this annual symposium to advance the field, and we are extremely grateful for the support of the Wintermann Foundation to make new breakthroughs possible.”

Mayor Sylvester Turner, TMC CEO Bill McKeon, Governor Greg Abbott, and others gave their remarks at the TMC3 Collaborative Building opening. Photo by Natalie Harms

Texas Medical Center opens first building in massive Helix Park project

tmc3

For nearly a decade, the Texas Medical Center and its partners have been working on the plans for Helix Park, a 37-acre campus expansion of TMC. As of this week, the first building has opened its doors to the public.

The TMC3 Collaborative Building officially opened today to a crowd of media, public officials, and health care executives. The institutional agnostic, 250,000-square-foot building will anchor Helix Park and house research initiatives from the four founding partners: Texas Medical Center, The University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and The University of Texas Health Science Center at Houston.

“Today, we lay the cornerstone of a new campus fully dedicated to streamlining the commercialization of life-changing innovations in medicine and technologies,” William McKeon, president and CEO of TMC, says at the event. “We are incredibly excited to both welcome our founding institutions and industry partners to the Collaborative Building and to invite the community to experience the Helix Park campus and its beautiful parks with a series of special events in the months ahead."

Established to be a place for academic institution collaboration, the building — designed by Boston-based Elkus Manfredi Architects — will have wet laboratories, office space, and event facilities. Two venture groups — Portal Innovations and the TMC Venture Fund — will also move into the building.

Each institution will bring in select programs and initiatives. MD Anderson will house two institutions within the new building, including the James P. Allison Institute focused on immunotherapy and the Institute for Data Science in Oncology.

"The future of life sciences in Houston is brighter than ever before as we come together to officially open the TMC3 Collaborative Building,” Dr. Peter WT Pisters, president of MD Anderson, says. “Our clinicians and scientists work daily to advance innovations in cancer research and care – all of which will be amplified in this new environment within Helix Park that further cultivates collaboration, connectivity, and creativity.”

UTHealth will move its Texas Therapeutics Institute into the facility.

“With a shared commitment to improving the health and well-being of individuals and communities, we are bringing together academics and industry to accelerate discovery and medical breakthroughs,” Dr. Giuseppe N. Colasurdo, president and Alkek-Williams Distinguished Chair at UTHealth Houston, says. “Through the Texas Therapeutics Institute — already a signature collaborative enterprise at UTHealth Houston — our world-renowned leaders in therapeutic antibody development will have the opportunity to work closely with other leading researchers in the Texas Medical Center, greatly enhancing our collective ability to translate discoveries and ideas into effective treatments.”

Texas A&M, which has worked with Houston Methodist to develop its engineering medical program, will operate its Texas A&M Health’s Institute of Biosciences and Technology in the new space.

“As we open this state-of-the-art facility, we’re opening the door to a new era of collaboration. This building signifies the dismantling of silos to deliver game-changing therapies for the toughest diseases impacting Texans and citizens worldwide,” said John Sharp, Chancellor of The Texas A&M University System. “Texas A&M Health’s Institute of Biosciences and Technology has long been a trailblazer in drug discovery, and now, in the heart of this resource-rich ecosystem of the Texas Medical Center, we’re taking it up a notch. By positioning our scientists near their peers and esteemed clinicians, we’re igniting a spark that will fuel innovation and forge dynamic research programs.”

The next aspect of Helix Park to deliver will be the Dynamic One, a 700,000-square-foot industry research facility. Several other buildings, including a hotel, residential tower, and mixed-use building, are expected to deliver over the next few years. The "spine" of the project is six linked green spaces, designed by landscape architect Mikyoung Kim, that form an 18.7-acre campus, which is shaped like a DNA helix, hence the project's name.

At the opening event, leaders discussed the annual impact of over $5.4 billion expected after the campus is completed, and the 23,000 permanent new jobs and 19,000 construction jobs anticipated from Helix Park.

"Texas truly is the home of innovation. Our energy innovations are legendary, as are our innovations in space," says Texas Governor Greg Abbott, naming several of the state's innovative accomplishments. "Long before all of this innovation we're seeing now, Texas was the home of the Texas Medical Center."

Mayor Sylvester Turner spoke to the importance of collaboration.

"Individually, you can do things very well. Collectively, you can be transformational," he says. "One thing about this city, collaboration is the key. When we play well together, and when we build an integrated, robust ecosystem, everyone wins. That's Houston, and that's the way we operate."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston's Texas Medical Center wins prestigious global award recognizing leaders in life science innovation

new bling

Last month, a global organization honored innovation leaders in life sciences, and the Texas Medical Center was among the recipients of the prestigious awards program.

The 18th annual Prix Galien Awards Gala awarded TMC Innovation with the win in the "Incubators, Accelerators and Equity" category. The Galien Foundation created the awards program in 1970 in honor of Galien, the father of medical science and modern pharmacology. Alongside TMC, the other winners represented biotech, digital health, startups, and more.

"We are super proud of this distinction," Tom Luby, director of TMC Innovation says at Envision 2024 last month, crediting the TMCi team and TMC leadership for the award. "We lean on a lot of advisers and experts — people who volunteer their time to work with startups. Without (them), we would not have been successful."

Luby explains that a Prix Galien Award holds a Nobel Prize level of significance for the community.

TMCi was named a finalist in August, and competed against programs from Cedars-Sinai, Mayo Foundation for Medical Education and Research, TechConnect, and more.

"The Awards Committee is honored to witness the exceptional dedication and creativity of our nominees as they turn visionary ideas into transformative solutions for patients worldwide," says Michael Rosenblatt, chair of the Prix Galien USA Awards Committee, in a news release. "Their unwavering commitment to advancing patient care is truly commendable, and we are honored to celebrate their outstanding contributions to global health."

The award is displayed at TMC Innovation's office, located in the medical center at 2450 Holcombe Blvd.

Houston energy transition tech SPAC goes public through IPO

BLANK CHECK

Houston-based CO2 Energy Transition Corp. — a “blank check” company initially targeting the carbon capture, utilization, and storage (CCUS) sector — closed November 22 on its IPO, selling 6 million units at $10 apiece.

“Blank check” companies are formally known as special purpose acquisition companies (SPACs). A SPAC aims to complete a merger, acquisition, share exchange, share purchase, reorganization or similar business combination in certain business sectors. CO2 Energy Transition will target companies valued at $150 million to $250 million.

Each CO2 Energy Transition unit consists of one share of common stock, one warrant to purchase one share of common stock at a per-share price of $11.50, and the right to receive one-eighth of a share of common stock based on certain business conditions being met.

The IPO also included the full exercise of the underwriter’s option to buy 900,000 units to cover over-allotments. Kingswood Capital Partners LLC was the sole underwriter.

Gross proceeds from the IPO totaled $69 million. The money will enable the company to pursue CCUS opportunities.

“Recent bipartisan support for carbon capture legislation heavily emphasized the government’s willingness to advance and support technologies for carbon capture, utilization, storage, and other purposes as efforts to reduce greenhouse gas emissions [continue],” Co2 Energy Transition says in an October 2024 filing with the U.S. Securities and Exchange Commission (SEC).

Brady Rogers is president and CEO of CO2 Energy Transition. He also is CEO of Carbon Capture Development Co., a Los Angeles-based developer of direct air capture (DAC) technology, and president of Houston-based Antelope Energy Partners LLC, a provider of oil and gas services.

------

This article originally ran on EnergyCapital.

Mastering control room management for smoother critical infrastructure operations

Up to Date

Control room management (CRM) systems play an integral role in ensuring the safe and efficient remote operations of automated processes for the world's most critical infrastructures (CI). If anything goes wrong with these CIs, the risks are major: loss of life or catastrophic environmental disasters. For this reason, rigorous regulatory requirements are crucial.

CRM systems give operators the ability to automate and take control of CI processes, giving operators situational awareness and real-time visibility of remote assets. This minimizes the need for manual work and inspection, and scales a company's ability to safely manage many assets over a large geographical area from one control room.

Most CI have to handle hazardous material in some, if not all, of their operational areas. Though different by industry, regulations and oversight are extremely necessary.

ICS (Industrial Control Systems) and CRM tools are key components of real-time monitoring for advanced warning and emergency alarming. The combination of a “green, amber, red” alert on the screen of an operator's control console will prompt them to respond, and potentially lead to following emergency shut-down response procedures. Training and testing of the control systems and their related standards, procedures, and activities are all recorded in a system of record in compliance with regulatory requirements.

Current challenges
One of the biggest challenges is the ability to easily aggregate the data from the many different systems and integrate them with the operator's daily activity and responses to the many notifications they receive. This makes it difficult for handover, when a new control room operator comes in fresh to take over from the operator coming off duty. Ensuring a clean and clear handover that encompasses all the pertinent information, so that the new operator can take over the console with ease and clarity, is much more difficult than some would imagine.

Another issue is the sheer volume of data. When you have thousands of sensors streaming data, it is not unrealistic for a console to receive a few thousand data points per second. Performance and continuity are priorities on a CI control room console(s). So there is no room for error — meaning there is no room for big (quite literally) data.

All of this means that real-time data must be pushed off the operational and process control network and moved into an area where there are no controls, but big data can be stored to produce big-data analytic capabilities, enabling AI, machine learning, and other data science.

Controller/operator fatigue is also an issue. Manual tracking, documenting, and record-keeping increases fatigue, leading to more mistakes and omissions.

Opportunities for improvement
The Houston-based Tory Technologies, Inc.is a corporation specializing in advanced software applications, creating and integrating various innovative technologies, and providing solutions for control room management and electronic flow measurement data management.

Tory Technologies, Inc. can help with the auto population of forms, inclusion of historical alarms and responses, and easy handover of control with active/open issues highlighted, making for an easier transition from one operator to the next.

"CRM is essential for keeping operations safe and efficient in industries where mistakes can lead to serious problems," says Juan Torres, director of operations - MaCRoM at Tory Technologies, Inc. "While many control rooms have worked hard to meet compliance standards, challenges remain that can affect performance and safety. It's not enough to just meet the basic rules; we need to go further by using smarter tools and strategies that make CRM more than just compliant, but truly effective."

Shaun Six, president of UTSI International, notes that, "CRM solutions are scalable. A smart integration with relevant systems and related data will reduce 'white noise' and increase relevance of data being displayed at the right time, or recalled when most helpful."

The future state
Offering CRM as a service for non-regulated control rooms will give economies of scale to critical infrastructure operators, which will allow dispatching, troubleshooting, and network monitoring so operators can focus on more value-add activities.

It can also virtualize network monitoring, ensuring that field machines and edge computers are compliant with industry and company standards and are not exposed to external threats.

Even better: Much of this can be automated. Smart tools can look through each device and test that passwords are changed, configurations are secure, and firmware/software has been properly patched or safeguarded against known exploits.

The sheer volume of data from these exercises can be overwhelming to operators. But a trained professional can easily filter and curate this data, cutting through the noise and helping asset owners address high-risk/high-probability exploits and plan/manage them.

Ultimately, the goal is to make control rooms efficient, getting the right information to the right people at the right time, while also retaining and maintaining required documents and data, ensuring an operators “license to operator” is uninterrupted and easily accessible to external parties when requested or needed.

Integrating smart CRM systems, network monitoring tools, and testing/validating processes and procedures are all easily accessible with current technological capabilities and availability, letting operators focus on the task at hand with ease and peace of mind.